NCT02948075 2018-06-27
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NewVac LLC
Phase 2 Completed
Clinical Trials
5 trialsNCT01486277 2016-11-03
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT02728492 2016-05-03
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NewVac LLC
Phase 1 Completed
NCT00677105 2012-09-17
A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1 Completed
NCT00676728 2012-09-14
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1 Terminated